Giorgio Parmiani
#129,822
Most Influential Person Now
Researcher
Giorgio Parmiani's AcademicInfluence.com Rankings
Giorgio Parmianibiology Degrees
Biology
#8479
World Rank
#11563
Historical Rank
Immunology
#487
World Rank
#504
Historical Rank

Download Badge
Biology
Giorgio Parmiani's Degrees
- PhD Immunology University of Milan
- Masters Biotechnology University of Milan
- Bachelors Biology University of Milan
Similar Degrees You Can Earn
Why Is Giorgio Parmiani Influential?
(Suggest an Edit or Addition)Giorgio Parmiani's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Phenotypic characterization of human colorectal cancer stem cells (2007) (2160)
- Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 (1999) (854)
- A listing of human tumor antigens recognized by T cells (2001) (807)
- Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles (2002) (746)
- Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. (2007) (678)
- Therapeutic vaccines for cancer: an overview of clinical trials (2014) (610)
- Interleukin-12: Biological Properties and Clinical Application (2007) (564)
- A listing of human tumor antigens recognized by T cells: March 2004 update (2005) (483)
- Tumour-released exosomes and their implications in cancer immunity (2008) (481)
- Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. (2005) (480)
- Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. (2006) (478)
- Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 (1995) (447)
- Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? (2002) (432)
- Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. (2012) (432)
- Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. (2004) (394)
- Tumor-released microvesicles as vehicles of immunosuppression. (2007) (393)
- Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. (2002) (387)
- Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo (1991) (315)
- Expression of MAGE genes in primary and metastatic cutaneous melanoma (1995) (297)
- Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. (1996) (296)
- Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients (2010) (295)
- Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction (2002) (293)
- Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. (2006) (281)
- A clinical development paradigm for cancer vaccines and related biologics. (2007) (274)
- LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites (2010) (264)
- Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. (2003) (259)
- Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. (2012) (258)
- Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes (1994) (257)
- Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. (2001) (250)
- Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. (2008) (242)
- Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. (2006) (241)
- Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. (1995) (240)
- Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes (1995) (218)
- HOXB7 constitutively activates basic fibroblast growth factor in melanomas (1996) (218)
- Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. (1992) (215)
- BRAF alterations are associated with complex mutational profiles in malignant melanoma (2004) (212)
- An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions (1999) (212)
- Human NK Cells Selective Targeting of Colon Cancer–Initiating Cells: A Role for Natural Cytotoxicity Receptors and MHC Class I Molecules (2013) (209)
- beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. (1998) (207)
- Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35) (1996) (196)
- Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. (2003) (193)
- Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. (2001) (191)
- Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma (1993) (184)
- Melanoma cells and normal melanocytes share antigens recognized by HLA- A2-restricted cytotoxic T cell clones from melanoma patients (1993) (181)
- Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study (2015) (178)
- Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma (2006) (165)
- Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. (1998) (164)
- Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1 (2007) (158)
- Translation of a Retained Intron in Tyrosinase-related Protein (TRP) 2 mRNA Generates a New Cytotoxic T Lymphocyte (CTL)-defined and Shared Human Melanoma Antigen Not Expressed in Normal Cells of the Melanocytic Lineage (1998) (156)
- Defining the critical hurdles in cancer immunotherapy (2011) (152)
- Tumour-associated transplantation antigens of chemically induced sarcomata cross reacting with allogeneic histocompatibility antigens (1975) (140)
- CD4 T cells inhibit in vivo the CD8‐mediated immune response against murine colon carcinoma cells transduced with interleukin‐12 genes (1995) (137)
- Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. (1993) (134)
- Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells1 (2003) (130)
- A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients (2006) (128)
- Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. (2013) (128)
- Targeting TNF-α to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy (2012) (127)
- Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer (2004) (127)
- Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. (2006) (122)
- Consensus nomenclature for CD8+ T cell phenotypes in cancer (2015) (118)
- Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. (1986) (116)
- Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. (1989) (115)
- Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. (1997) (114)
- Clonal analysis of cytotoxic T‐lymphocyte response to autologous human metastatic melanoma (1985) (113)
- Selective Histocompatibility Leukocyte Antigen (Hla)-A2 Loss Caused by Aberrant Pre-mRNA Splicing in 624mel28 Melanoma Cells (1999) (111)
- Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. (2015) (111)
- Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein. (1993) (110)
- A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. (1999) (110)
- Cytokines in cancer therapy. (2000) (108)
- Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. (1996) (102)
- Role of Cross-Talk between IFN-α-Induced Monocyte-Derived Dendritic Cells and NK Cells in Priming CD8+ T Cell Responses against Human Tumor Antigens1 (2004) (101)
- Heterogeneity in human melanoma cell adhesion to cytokine activated endothelial cells correlates with VLA-4 expression. (1991) (101)
- T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2- restricted and melanocyte-lineage-specific CTL clone (1993) (101)
- Expression of cytokine genes, including IL‐6, in human malignant melanoma cell lines (1992) (100)
- Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. (1996) (98)
- Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. (1995) (97)
- The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. (2003) (97)
- Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme (2014) (96)
- Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4 (2014) (96)
- Clonal analysis of the cytolytic T-cell response to human tumors. (1987) (95)
- Heterogeneity for integrin expression and cytokine‐mediated VLA modulation can influence the adhesion of human melanoma cells to extracellular matrix proteins (1991) (93)
- Immunology of cancer stem cells in solid tumours. A review. (2014) (92)
- Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. (1998) (91)
- Effect Of Human Natural Killer and γδ T Cells on the Growth of Human Autologous Melanoma Xenografts in SCID Mice (2004) (89)
- Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells. (2001) (88)
- Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cells. (1992) (88)
- Potent Phagocytic Activity Discriminates Metastatic and Primary Human Malignant Melanomas: A Key Role of Ezrin (2003) (87)
- Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. (1996) (87)
- Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination (2004) (87)
- Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). (1998) (86)
- Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. (1993) (85)
- Cytokine‐mediated modulation of HLA‐class II, ICAM‐1, LFA‐3 and tumor‐associated antigen profile of melanoma cells. comparison with anti‐proliferative activity by RIL1‐β, RTNF‐α, RIFN‐γ, RIl4 and their combinations (1990) (83)
- Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? (1990) (83)
- Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. (1996) (83)
- Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. (2010) (83)
- T‐cell recognition of melanoma‐associated antigens (2000) (82)
- Immunology and immunotherapy of human cancer: present concepts and clinical developments. (2000) (82)
- An explanation of the variable clinical response to interleukin 2 and LAK cells. (1990) (82)
- Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy (2017) (82)
- Human melanoma cells with high susceptibility to cell‐mediated lysis can be identified on the basis of icam‐1 phenotype, vla profile and invasive ability (1990) (80)
- The susceptibility to natural killer cell‐mediated lysis of HLA class I‐positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles (1998) (77)
- In vitro anti‐tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5 (1993) (77)
- Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb. (1991) (76)
- Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? (2005) (75)
- Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. (1996) (74)
- Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. (2003) (73)
- Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal. (2000) (73)
- Genes involved in melanoma: an overview of INK4a and other loci. (1999) (72)
- Immunology and immunotherapy of colorectal cancer. (2003) (72)
- Detection of mutated BRAFV600E variant in circulating DNA of stage III–IV melanoma patients (2007) (71)
- Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors. (1998) (71)
- Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. (1998) (69)
- The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA‐DR antigens on the tumor cells (1984) (68)
- Heat Shock Proteins and Their Use as Anticancer Vaccines (2004) (68)
- Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. (1997) (67)
- NKG2D engagement of colorectal cancer‐specific T cells strengthens TCR‐mediated antigen stimulation and elicits TCR independent anti‐tumor activity (2003) (67)
- Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides (2012) (65)
- Melanoma immunology: past, present and future (2007) (64)
- Multipeptide vaccination in cancer patients (2009) (62)
- Role of the α5β1 Integrin Receptor in the Proliferative Response of Quiescent Human Melanoma Cells to Fibronectin (1992) (62)
- CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. (2008) (62)
- Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. (1999) (62)
- Heterogeneity of clones from a human metastatic melanoma detected by autologous cytotoxic T lymphocyte clones (1986) (61)
- Peptide-based vaccines for cancer therapy (2014) (60)
- CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation (2001) (59)
- Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity. (2006) (59)
- Expression of alien h‐2 specificities on a chemically induced balb/c fibrosarcoma (1977) (57)
- Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes (1993) (56)
- Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions. (1999) (55)
- Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. (1999) (55)
- Cytokine gene transduction in the immunotherapy of cancer. (1997) (54)
- Adoptive transfer of an anti‐MART‐127–35‐specific CD8+ T cell clone leads to immunoselection of human melanoma antigen‐loss variants in SCID mice (2003) (54)
- Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. (2003) (54)
- Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use (1994) (54)
- Differentiation of CD8+ T Cells from Tumor-Invaded and Tumor-Free Lymph Nodes of Melanoma Patients: Role of Common γ-Chain Cytokines1 (2003) (53)
- Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients (1994) (53)
- Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. (2009) (52)
- In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. (1990) (52)
- T-cell recognition of melanoma-associated antigens. (2000) (52)
- Tumor-infiltrating T cells--friend or foe of neoplastic cells? (2005) (50)
- Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96. (2005) (49)
- Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. (1995) (49)
- Identification of a Mutated Receptor-Like Protein Tyrosine Phosphatase κ as a Novel, Class II HLA-Restricted Melanoma Antigen1 (2003) (49)
- Genetic modification of a carcinoma with the IL‐4 gene increases the influx of dendritic cells relative to other cytokines (1997) (49)
- Differential patterns of HOX gene expression are associated with specific integrin and ICAM profiles in clonal populations isolated from a single human melanoma metastasis (1996) (48)
- Immunotherapy of melanoma. (2003) (48)
- Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols. (1996) (48)
- T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes (2015) (47)
- Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells (2002) (47)
- Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability (1997) (47)
- Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice. (2004) (46)
- Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes. (1988) (46)
- TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors (2009) (46)
- PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells. (2008) (45)
- Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype. (2005) (45)
- Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients (2017) (44)
- Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. (1994) (44)
- Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 (2013) (42)
- Factors, including transforming growth factor β, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells (1993) (42)
- Biochemical characterization of alien H-2 antigens expressed on a methylcholanthrene-induced tumor. (1979) (40)
- Local Adoptive Immunotherapy of Advanced Head and Neck Tumors with Lak Cells and Interleukin-2 (1990) (40)
- In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2 (1988) (39)
- Melanoma Cancer Stem Cells: Markers and Functions (2016) (38)
- International Meeting on Cancer Vaccines (2004) (38)
- IMPAIRED H‐2 EXPRESSION IN B 16 MELANOMA VARIANTS (1983) (37)
- An in vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different chemokines (1995) (37)
- Vaccination of patients with solid tumours. (2003) (37)
- Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention. (1986) (37)
- Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. (2003) (37)
- Immunomodulation in a Treatment Program Including Pre- and Post-Operative Interleukin-2 and Chemotherapy for Childhood Osteosarcoma (2003) (36)
- T‐cell‐receptor engagement and tumor ICAM‐1 up‐regulation are required to by‐pass low susceptibility of melanoma cells to autologous CTL‐mediated lysis (2009) (36)
- Differential susceptibility to recombinant interferon-gamma-induced HLA-DQ antigen modulation among clones from a human metastatic melanoma. (1987) (36)
- Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. (1990) (36)
- Universal and Stemness-Related Tumor Antigens: Potential Use in Cancer Immunotherapy (2007) (35)
- Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype (2005) (35)
- Expression of Interleukin 1α, Interleukin 6, and Tumor Necrosis Factor α Genes in Human Melanoma Clones Is Associated with That of Mutated N-RAS Oncogene (1994) (35)
- Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes. (1993) (35)
- NKG2D-Mediated Antitumor Activity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated from Melanoma Patients (2007) (35)
- Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity. (1998) (34)
- Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response (2013) (33)
- Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. (1996) (33)
- Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. (1996) (33)
- Non-carcinogenicity of hexamethylenetetramine in mice and rats. (1968) (33)
- MULTIPLE FOREIGN NON‐H‐2 DETERMINANTS ON THE SURFACE OF A CHEMICALLY‐INDUCED MURINE SARCOMA * (1977) (32)
- Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study. (1994) (31)
- Human Plasmacytoid Dendritic Cells Interact with gp96 via CD91 and Regulate Inflammatory Responses1 (2008) (31)
- Non-Redundant Role for IL-12 and IL-27 in Modulating Th2 Polarization of Carcinoembryonic Antigen Specific CD4 T Cells from Pancreatic Cancer Patients (2009) (31)
- Vaccination therapy in prostate cancer (2007) (30)
- Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer (2014) (30)
- Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. (1995) (29)
- Immunodepression During Urethane and N-Nitrosomethylurea Leukaemogenesis in Mice (1971) (29)
- T-cell response to unique and shared antigens and vaccination of cancer patients. (2002) (29)
- Heterogeneous susceptibility of human melanoma clones to monocyte cytotoxicity: Role of ICAM‐1 defined by antibody blocking and gene transfer (1992) (29)
- Effects of antitumour immunity on pregnancy in the mouse. (1973) (29)
- Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells. (2005) (29)
- Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M. (1995) (29)
- Multiple sub‐sets of Cd4+ and Cd8+ cytotoxic T‐cell clones directed to autologous human melanoma identified by cytokine profiles (1994) (28)
- Vaccination: role in metastatic melanoma (2006) (28)
- Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha (2000) (28)
- Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A et al.. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25: 3357-3364 (2006) (27)
- Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study (2016) (27)
- Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA‐restricted cytotoxic T cells (1997) (27)
- Jmmunodepressive and Leukemogenic Effects of Urethan in C3Hf and SWR Mice∗ (1969) (26)
- Effect of anti‐embryo immunization on methylcholanthrene‐induced sarcoma growth in BALB/c mice (1974) (26)
- Immunogenic strength of sarcomas induced by methylcholanthrene in millipore filter diffusion chambers. (1973) (25)
- Cross‐reactions between tumor cells and allogeneic normal tissues. inhibition of a syngeneic lymphoma outgrowth in h‐2 and non‐h‐2 alloimmune balb/c mice (1982) (25)
- TCR beta-chain variable region-driven selection and massive expansion of HLA-class I-restricted antitumor CTL lines from HLA-A*0201+ melanoma patients. (1997) (25)
- Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability (1997) (24)
- Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine (1999) (24)
- Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity? (2009) (24)
- T cell infiltration and prognosis in HCC patients. (2006) (23)
- T cell responses in colorectal cancer patients: Evidence for class II HLA‐restricted recognition of shared tumor‐associated antigens (2000) (23)
- Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial. (2003) (23)
- Selective purging by human interleukin‐2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells (1991) (23)
- Low TCR avidity and lack of tumor cell recognition in CD8+ T cells primed with the CEA-analogue CAP1-6D peptide (2007) (22)
- Immune‐depressive effect of urethan on the homograft response in mice (1970) (22)
- Lysis by activated lymphocytes of melanoma and small cell lung cancer cells surviving in vitro treatment with mafosfamide. (1987) (22)
- N-Nitroso Compounds in the Environment. (1975) (22)
- Autologous Versus Allogeneic Cell-Based Vaccines? (2011) (22)
- Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H‐2 associativity of variant‐specific antigens (1982) (22)
- Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function. (2002) (22)
- Conserved TCR usage by HLA-Cw* 1601-restricted T cell clones recognizing melanoma antigens. (1996) (22)
- Immunogenicity of the ALLAVGATK (gp10017 – 25) peptide in HLA‐A3.1 melanoma patients (1998) (21)
- A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma (2014) (21)
- Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy (2001) (21)
- Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene. (1994) (21)
- Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung (2004) (21)
- Melanoma antigens and their recognition by T cells. (2001) (21)
- Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report. (1994) (20)
- In vitro "spontaneous" neoplastic transformation of mouse fibroblasts in diffusion chambers. (1971) (20)
- In vivo characterization of a doxorubicin resistant B16 melanoma cell line. (1986) (20)
- Allostimulation of patients' lymphocytes generates both T and NK-like cells cytotoxic for autologous melanoma. (1985) (20)
- High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition (1999) (20)
- Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells. (1983) (20)
- Clinical and immunologic responses in melanoma patients vaccinated with MAGE‐A3‐genetically modified lymphocytes (2013) (20)
- Immune response to autologous human melanoma: implication of class I and II MHC products. (1986) (19)
- Autologous tumor-derived HSPPC-96 vs. physician's choice (PC) in a randomized phase III trial in stage IV melanoma. (2006) (19)
- Cytokine-based gene therapy of human tumors. An overview. (1996) (19)
- Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma. (1992) (19)
- Human melanocytes and melanomas express novel mRNA isoforms of the tyrosinase-related protein-2/DOPAchrome tautomerase gene: molecular and functional characterization. (2000) (19)
- Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes (2001) (19)
- Mitogenic activity of fibronectin and laminin on human melanoma is mediated by β1 integrins: 251 (1993) (19)
- Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers. (1997) (19)
- Proliferative and/or cytotoxic activity of lymphocyte clones to autologous human melanoma (1988) (19)
- Activation of ras oncogenes and expression of tumor‐specific transplantation antigens in methylcholanthrene‐induced murine fibrosarcomas (1991) (18)
- Transplacental Toxicity and Carcinogenesis Studies in Rats with Hexamethylenetetramine (1970) (18)
- Human allogeneic melanoma‐reactive T‐helper lymphocyte clones: Functional analysis of lymphocyte‐melanoma interactions (1991) (18)
- Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes (2004) (18)
- Cytokine gene transduction in tumor cells: interleukin (IL)-2 or IL-4 gene transfer in human melanoma cells. (1994) (18)
- Regulated expression of vascular cell adhesion molecule-1 in human malignant melanoma. (1992) (18)
- Gene transfer in tumor therapy. (1994) (18)
- Heat shock proteins gp96 as immunogens in cancer patients (2006) (17)
- Limitations of the cancer stem cell theory (2008) (17)
- Melanoma immunotherapy: new dreams or solid hopes? (1996) (17)
- Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy (2015) (16)
- Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy (2011) (16)
- Growth Characteristics of Human Colorectal and Non-Small Cell Lung Tumors Xenografted into Nude Mice: Possible Correlation with Prognosis (1986) (16)
- Alien histocompatibility antigens on tumor cells (1979) (16)
- Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2 (1993) (16)
- Tumor-associated transplantation antigen distinct from H-2k-like antigens on a BALB/c (H-2d) fibrosarcoma. (1978) (15)
- Tumour immunotherapy: the adjuvant treatment of the 21st century? (2000) (15)
- Two autologous melanoma‐specific and MHC‐restricted human T cell clones with identical intra‐tumour reactivity do not share the same TCR Vα and Vβ gene families (1991) (15)
- Human dendritic cells: natural adjuvants in antitumor immunotherapy. (1998) (14)
- Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP). (2013) (14)
- Immunohistochemical analysis of the T-cell receptor beta-chain variable regions expressed by T lymphocytes infiltrating primary human melanoma. (1998) (14)
- Future perspectives in specific immunotherapy of melanoma. (1998) (14)
- Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine (2002) (14)
- Human Lymphocyte Activation Gene-3 Molecules Expressed by Activated T Cells Deliver Costimulation Signal for Dendritic Cell Activation1 (2008) (14)
- P-glycoprotein gene amplification and expression in multidrug-resistant murine P388 and B16 cell lines. (1989) (14)
- CEA and NCA Expressed by Colon Carcinoma Cells Affect their Interaction with and Lysability by Activated Lymphocytes (1992) (14)
- Induction and functional characterization of β 2‐microglobulin (β2‐μ)‐free HLA class I heavy chains expressed by β2‐μ‐deficient human FO‐1 melanoma cells (1998) (13)
- Preparation of antigenically active membranes from solid murine lymphomas and fibrosarcomas. (1979) (13)
- Doxorubicin cellular pharmacokinetics and DNA breakage in a multi-drug resistant B16 melanoma cell line. (1988) (13)
- A human melanoma cell line transduced with an interleukin-4 gene by a retroviral vector releases biologically active IL-4 and maintains the original tumor antigenic phenotype. (1995) (13)
- Down-regulation of SPARC/osteonectin/BM-40 expression in methylcholanthrene-induced fibrosarcomas and in Kirsten-MSV transformed fibroblasts. (1991) (13)
- Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination. (1998) (13)
- DEPRESSION OF CELLULAR IMMUNE RESPONSE DURING SYNGENEIC PREGNANCY AS MEASURED BY THE GRAFT‐VERSUS-HOST REACTION (1975) (13)
- Tumorigenicity and dissemination of primary and metastatic human melanomas implanted into different sites in athymic nude mice. (1988) (12)
- Tumor rejection activity of antigens isolated from the membranes of a methylcholanthrene-induced sarcoma, C-1, bearing alien H-2 antigens. (1980) (12)
- N-RAS mutations and susceptibility to lymphokine-activated killer (LAK) cells in human melanoma (1994) (12)
- Active immunization of metastatic melanoma patients with IL-2 or IL-4 gene transfected, allogeneic melanoma cells. (1998) (12)
- Lymphotoxin gene expression by melanocytes and melanoma cell lines and persistence of unspliced mRNA (1993) (12)
- A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial. (2011) (12)
- Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP). (2013) (12)
- Role of the alpha 5 beta 1 integrin receptor in the proliferative response of quiescent human melanoma cells to fibronectin. (1992) (12)
- T-cell recognition of melanoma antigens and its therapeutic applications (1997) (11)
- Inhibition of Human Melanoma Growth in Nude Mice by Autologous, Alloactivated Peripheral Blood Lymphocytes (1984) (11)
- Erratum: In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5 (Int. J. Cancer, 54, 8-15 (1993)) (1993) (11)
- Cytotoxic T-lymphoc ' te clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A 2-restricted recognition of the melanoma antigen MelanA / MART-1 (2005) (11)
- Pre-clinical and clinical aspects of peptide-based vaccine against human solid tumors. (2011) (11)
- In vivo reexpression of H-2 antigens in B16 melanoma cells. (1985) (11)
- Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinations. (1990) (11)
- Induction of Both CD8+ and CD4+ T-Cell–Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1 (2008) (11)
- Immunological approach to gene therapy of human cancer: improvements through the understanding of mechanism(s) (1998) (11)
- Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients (2018) (11)
- LOSS OF POLYMORPHIC RESTRICTION FRAGMENTS OF CLASS I AND CLASS II MHC GENES IN A MALIGNANT MELANOMA (1986) (10)
- Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients. (2013) (10)
- Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation. (1989) (10)
- Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin‐2 and lymphokine activated killer cells. A pilot study (1992) (10)
- Expression of retrovirus-related, cytotoxic T lymphocyte- and transplantation-defined antigens in NIH/3T3 transfectants after a single passage in nude mice. (1989) (9)
- Tumor-associated alien alloantigens of BALB/c tumors encoded by the MHC and by non-H-2 genes: a histogenetic study. (1980) (9)
- Effect of different sera on growth and "spontaneous" neoplastic transformation of mouse fibroblasts in vitro. (1974) (9)
- Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules. (1992) (9)
- Multiple VLA antigens on a subset of melanoma clones. (1990) (9)
- β1-Integrins on Melanoma Clones Regulate the Interaction with Autologous Cytolytic T-Cell Clones (1992) (9)
- ALIEN ANTIGENS ON TUMOUR CELLS REVISITED (1984) (8)
- Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells (2004) (8)
- Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones. (2002) (8)
- Preliminary results of contrast‐enhanced sonography in the evaluation of the response of uveal melanoma to gamma‐knife radiosurgery (2015) (8)
- A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial. (2015) (8)
- Regression of established liver tumor induced by monoepitopic peptide-based immunotherapy (2005) (8)
- Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: The pattern of in vitro reactivity predicts the in vivo effect on different tumours (2005) (8)
- Osteonectin transcript and metastatic behavior in v‐Ki‐ras transformed fibroblasts (1989) (8)
- Alien H-2 antigens (H-2k) appearing on a methylcholanthrene-induced tumor (H-2d): biochemical characterization. (1980) (8)
- Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells (2004) (7)
- Human CD 4 Lymphocytes Specifically Recognize a Peptide Representing the Fusion Region of the Hybrid Protein pml / RARa Present in Acute Promyelocytic Leukemia Cells (2003) (7)
- Tumor necrosis factor/cachectin and related cytokines (1989) (7)
- An autologous T cell clone overcomes intra-melanoma heterogeneity for susceptibility to cell-mediated lysis by using multiple lytic mechanisms: in vitro and in vivo analysis. (1991) (7)
- International Meeting “Immunotherapy of Cancer: Challenges and Needs” (2007) (7)
- Chromosomal changes associated with urethan leukemogenesis in mice (1969) (7)
- Effect of Prolonged Subcutaneous Administration of Interleukin-2 on the Orcadian Rhythms of Cortisol and Beta-Endorphin in Advanced Small Cell Lung Cancer Patients (1991) (7)
- T lymphocytes can mediate lysis of autologous melanoma cells by multiple mechanisms: Evidence with a single T cell clone (2005) (7)
- Anti-H-2 alloantibodies elicited by syngeneic immunizations with a chemically induced fibrosarcoma (1978) (7)
- Genetic control of in vivo immunity to tumor‐specific transplantation antigens of chemically induced murine fibrosarcomas (1979) (7)
- Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: Characterization of the effector population and evidence for the role of the host's non-T cells (2004) (6)
- Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial. (2012) (6)
- The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases. (2012) (6)
- The early antitumor immune response is necessary for tumor growth (2012) (6)
- Alien Histocompatibility Determinants on the Cell Surface of Sarcomas Induced by Methylcholanthrene. II. in Vitro Serological Studies 1 (1977) (6)
- NMU-1, a new transplantable mouse lung tumor: biological and chemosensitivity properties in vivo. (1985) (6)
- Immunotherap y for colon cancer (1999) (6)
- Nonimmunogenic sarcomas induced by 3-methylcholanthrene treatment of murine fibroblasts in diffusion chambers. (1975) (6)
- ORIGINAL H‐2d AND FOREIGN H ‐ 2k ‐ LIKE ANTIGENS ARE INDEPENDENT ENTITIES ON A CHEMICALLY INDUCED SARCOMA (1978) (6)
- Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma (1995) (6)
- Adoptive immunotherapy of cancer with immune and activated lymphocytes: Experimental and clinical studies (1986) (6)
- Skin-graft rejection during lymphomagenesis in urethan-treated mice. (1971) (6)
- Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs (2004) (6)
- Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients and modulation by GM-CSF-based anti-tumor vaccine (2007) (6)
- Tumor Immunology: Molecularly Defined Antigens and Clinical Applications (2003) (6)
- Induction and functional characterization of beta2-microglobulin (beta2-mu)-free HLA class I heavy chains expressed by beta2-mu-deficient human FO-1 melanoma cells. (1998) (6)
- Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes (2005) (6)
- Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. V. Chromosomal mapping of the immunodominant cytotoxic T-cell target-1 (CTT-1) (2004) (5)
- Increased Oncogenic Effect of a Low Dose of Methylcholanthrene in Immunodepressed Mice (1971) (5)
- Phase II study of HSPPC-96 in combination with GM-CSF and IFN-α in stage IV malignant melanoma. (2004) (5)
- Mechanisms for Tumor Killing and Use Fas / Fas Ligand-Independent CTL Clones Resist Fas Ligand-Induced Apoptosis + and CD 8 + Human Melanoma-Reactive CD 4 (1998) (5)
- HLA Binding Characteristics and Generation of Cytotoxic Lymphocytes against Peptides Derived from Oncogenic Proteins (1997) (5)
- Lack of anti-TSTA antibodies in mice immunized with a methylcholanthrene-induced fibrosarcoma (1981) (5)
- Tumor-cell-targeted cytokine gene therapy. (1991) (5)
- Can oncogene (RAS) activation predict susceptibility of human melanoma to activated lymphocytes and, therefore, the clinical response of such neoplasms to adoptive immunotherapy? (1992) (5)
- Awareness and understanding of cancer immunotherapy in Europe (2014) (5)
- Efficacy and safety data from elderly patients with pretreated advanced melanoma in the Italian cohort of ipilimumab expanded access programme (EAP). (2013) (5)
- Lack of identity between TSTA and alien antigens of methylcholanthrene-induced murine sarcomas. (1980) (5)
- Resistance of Cancer Stem Cells to Cell-Mediated Immune Responses (2015) (5)
- Tumor antigens recognized by T cells and antibodies (2003) (5)
- Retroviral heterogeneity in mouse lymphomas. (1988) (5)
- Cytokine gene transfer in tumor cells as an approach to antitumor therapy (1992) (5)
- DBA/2‐like minor histocompatibility antigens on a BALB/c lymphoma. A balb/c anti‐DBA/2 serum which lyses the tumor and blocks balb/c anti‐tumor and anti‐DBA/2 effectors (1985) (4)
- Expression of H-2 and viral antigens and resistance to the antitumor lysis of tunicamycin-treated MBL-2 lymphoma cells. (1983) (4)
- Chemokine Receptor 7, A New Player in Regulating Apoptosis of CD8+ T Cells in Cancer Patients (2005) (4)
- LACK OF H‐2Ld LOCUS PRODUCTS ON A BALB/c FIBROSARCOMA EXPRESSING H‐2k‐LIKE ALIEN ANTIGENS (1983) (4)
- COINCIDENT EFFECT IN THE GRAFT‐VERSUS‐HOST REACTION OF BALB/c LYMPHOID CELLS DERIVED FROM MICE IMMUNE EITHER TO ALLOGENEIC NORMAL TISSUE OR TO SYNGENEIC CHEMICALLYINDUCED FIBROSARCOMATA (1977) (4)
- Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors (2005) (4)
- Eradication of a disseminated mouse lymphoma by 1,3‐BIS(2‐chloroethyl)‐1‐nitrosourea is immunologically mediated and accompanied by de novo generation of anti‐tumor cytotoxicity (1990) (4)
- The Role of Cytokines in the Modulation of Cell Surface Antigens of Human Melanoma (1993) (4)
- A new Procedure for Large Scale Production and Freezing of Lymphokine Activated Killer (LAK) Cells to be used in Adoptive Immunotherapy of Cancer (1988) (4)
- Antigens of chemically induced tumors. (1976) (4)
- Control of human melanoma growth in nude mice by autologous allo‐activated peripheral blood lymphocytes (1986) (3)
- Treatment of a low immunogenic experimental tumour with alloactivated or tumour-immune lymphocytes. (1987) (3)
- The undefined relationship between tumor antigens and histocompatibility antigens on cancer cells (1980) (3)
- The Italian Network for Tumor Biotherapy (NIBIT). Sharing Visions, Goals and Efforts at European Level (2008) (3)
- Adjuvant multipeptide vaccination in high-risk early melanoma patients (2008) (3)
- Carcinoma-Specific T Cells Expansion of Melanoma- and Colon Mediates In Vitro Activation and In Vivo Human Tumor-Derived Heat Shock Protein 96 (2003) (3)
- Two autologous melanoma-specific and MHC-restricted human T cell clones with identical intra-tumour reactivity do not share the same TCR V alpha and V beta gene families. (1991) (3)
- PHENOTYPIC HETEROGENEITY OF HLA PRODUCTS ON HUMAN MELANOMA CELLS (1986) (3)
- Increasing immunogenicity of cancer vaccines to improve their clinical outcome (2013) (3)
- Surgical Treatment of Melanoma: A Survey of Italian Hospitals (2013) (3)
- Follow-Up of Melanoma: A Survey of Italian Hospitals (2013) (3)
- Vaccination with survivin and PSMA-derived peptides for controlling biochemical recurrence in prostate cancer: A pilot study. (2016) (3)
- Gene therapy of melanoma (2003) (3)
- Cancer vaccination. (1999) (3)
- BIOCHEMICAL ANALYSIS OF A PUBLIC H‐2 SPECIFICITY REVEALED BY AN ANOMALOUS REACTION OF AN ALLOANTISERUM WITH A CHEMICALLY INDUCED C57BL/10 FIBROSARCOMA (1982) (3)
- Syngeneic Antitumor and Antiembryo Immunization Affecting Pregnancy in Mice 1 (1976) (3)
- Lack of suppressive activity of human primary melanoma cells on the activation of autologous lymphocytes (2004) (3)
- The Italian Network for Tumor Biotherapy (NIBIT): Getting together to push the field forward (2008) (3)
- Cell surface antigens of chemically induced fibrosarcomas: detection by a monoclonal antibody of a tumor-restricted Mr 12,000 protein gag antigen encoded by a dual-tropic murine leukemia virus. (1985) (2)
- Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cells. (1991) (2)
- NKG 2 D-Mediated AntitumorActivity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated fromMelanoma Patients (2007) (2)
- When transgenes shape immunity: cancer immune‐gene therapy (2012) (2)
- Inhibition of the YC8 lymphoma growth by alloimmunization with normal cells. (1981) (2)
- Gene therapy in melanoma. (2001) (2)
- Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2 - activated lymphocytes (LAK) (1988) (2)
- Histocompatibility Antigens on the Cell Surface of Tumors (1983) (2)
- Conference on cancer vaccines (2000) (2)
- Role of the Immune System in the Growth of an Isotransplanted Urethan-Induced Lymphosarcoma (1969) (2)
- T cell response to tumor antigens and its therapeutic use in cancer patients. (2001) (2)
- A merging duo in melanoma formation. (2005) (2)
- H‐2K RESTRICTION OF THE T CELL‐MEDIATED LYSIS OF A CHEMICALLY‐INDUCED BALB/c FIBROSARCOMA (1983) (2)
- Immunotherapy for colon cancer. (1999) (2)
- Analysis of the cellular immune response to and adoptive immunotherapy of a BALB/c lymphoma that cross-reacts with normal DBA/2 cells (2004) (2)
- Generation of TSTA diversity (1983) (2)
- Immunobiology and Use in Clinical Trials Unique Human Tumor Antigens: (2)
- Strain polymorphism and tentative mapping of mouse ornithine decarboxylase. (1988) (2)
- Re-visiting Prehn's hypothesis in the human melanoma system (2012) (2)
- Microenvironment and Immunology Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-In fi ltrating T Lymphocytes (2012) (2)
- Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicin (2004) (2)
- Awareness and understanding of cancer immunotherapy in Europe. (2013) (2)
- Autologous cellular immune response in cancer today (1991) (2)
- Beta 1-integrins on melanoma clones regulate the interaction with autologous cytolytic T-cell clones. (1992) (2)
- Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model. (1990) (2)
- Melanoma: The Milan Melanoma Cell Lines (2002) (2)
- Induction of autologous human melanoma killer lymphocytes by allostimulation (1985) (1)
- Immunogenic Neoplastic Clones Derived in Vitro from an Originally Non-immunogenic BALB/c Fibrosarcoma 1 (1977) (1)
- Melanoma Antigens Derived from Tyrosinase-Related Protein-2 Novel HLA-Cw 8-Restricted T Cell Epitopes (1999) (1)
- Biochemical characterization of the anomalous reaction of anti-H-2b alloantiserum with a chemically induced sarcoma of H-2k origin. (1981) (1)
- Vaccine Therapy of Cancer (2002) (1)
- H-2 class I gene analysis in 3-methylcholanthrene-induced murine fibrosarcomas. (1990) (1)
- Tumor-Derived Exosomes as Dendritic Cell Modulators (2009) (1)
- Immune mechanisms in neoplasia (2004) (1)
- Genetic control of responsiveness to the tumor-associated transplantation antigen of a chemically induced murine fibrosarcoma (1978) (1)
- T cell-defined melanoma antigens: toward a tumour-specific immunotherapy of the disease. (1993) (1)
- Adoptive Immunotherapy of Melanoma with Interleukin-2 and Lymphocytes (1993) (1)
- Frequency of CTL precursors and effectors directed to a single peptide of melan-A/Mart-1: Evidence for heterogeneity among HLA-A*0201+melanoma patients (1997) (1)
- Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme. (1990) (1)
- Study of the immunogenic strength of sarcomas induced in diffusion chambers. (1972) (1)
- Abnormal expression of histocompatibility antigens on cancer cells. (1982) (1)
- Cancer vaccines. (2000) (1)
- Foxp 3 highCD 25 + LAG-3 Expression Defines a Subset of CD 4 Parmiani (2010) (1)
- Defective T helper activity in the spleen of BALB/c mice immune to a syngeneic fibrosarcoma (2004) (1)
- Neutrophils discriminate between G-CSF producing and non-producing colon carcinoma cells: correlation with tumor inhibition (1991) (1)
- What is new in melanoma research? Vaccines, Basic and Translational Research in 2003: report of a workshop at the Third Research Meeting on Melanoma, Milan, Italy, May 2003 (2004) (1)
- Cancer patients' lymphocytes contain CD3+CD4+cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells (2005) (1)
- Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosurea on spontaneous metastases of a non-immunogenic murine tumour (2005) (1)
- Histocompatibility antigens and tumour antigens (1980) (1)
- 11 Recent developments of immunotherapy in melanoma patients.The experience of Milano National Cancer Institute (1997) (1)
- Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme (2014) (1)
- Improved survival for stage III/IV melanoma from an unknown primary site (MUP): An Italian multicentric study. (2010) (1)
- Effect of anti-tumor immunity on pregnancy in the mouse. Abstr. (1973) (1)
- Optimized Analogues Altered Peptide Ligands : Role of MelanA / MART-1 T Cells by Melanoma-derived + Suboptimal Activation of CD 8 Updated Version (2003) (0)
- Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7–9, 2010 (2011) (0)
- Subject Index, Vol. 44, 1976 (1976) (0)
- Human tumor vaccines go molecular (1995) (0)
- MHC class I antigens and somatic mutants. (1987) (0)
- Hox gene expression in parallel clonal populations derived from a single human melanoma metastasis: 239 (1993) (0)
- 9 A phase I study of immunization with dendritic cells transduced with a vaccinia vector encoding the human tyrosinase gene in patients with metastatic melanoma (2004) (0)
- Treatment of stage IV melanoma patients with interleukin-2 (IL-2) and autologous tumor infiltrating lymphocytes (TIL): 291 (1993) (0)
- Vaccination-induced myeloid suppressor cells in melanoma: phenotypic and functional characterization (2007) (0)
- Interaction of Cytotoxic T Lymphocytes with Autologous Melanoma: Role of Adhesion Molecules and β1 Integrins (1993) (0)
- Tata and alien h-2 are distinct antigens on the cell surface of a chemically induced fibrosarcoma. Abstr. (1978) (0)
- Characterization of the immune profile of cancer stem cells isolated from human glioblastoma (2008) (0)
- Late abstracts 186–187 (2005) (0)
- Regulation and effect of TNFβ expression in melanoma cell lines: 283 (1993) (0)
- Inflammatory Responses with gp96 via CD91 and Regulate Human Plasmacytoid Dendritic Cells Interact (2008) (0)
- “Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 (2016) (0)
- Libri Ricevuti: Principles of Cancer Biotherapy (1992) (0)
- Serologically detected foreign alloantigens of a chemically induced murine sarcoma. Abstr. (1976) (0)
- Induction of myeloid cells with suppressive activity by human tumor-released microvesicles (2006) (0)
- Regulated Expression ofVascular Cell Adhesion Molecule-1 inHuman Malignant Melanoma (1992) (0)
- Biology of Amphibian Tumors (1970) (0)
- Immunotherapy of tumors. Introduction. (1994) (0)
- Evaluation of Myeloid Suppressive Cells in Peripheral Blood of Melanoma Patients and Their Modulation by A Heat-shock Protein (HSP)-96 and GM-CSF-based Vaccine (2005) (0)
- CCN3/NOV matricellular protein is expressed in melanoma progression (2006) (0)
- TCR Variable Regions T Lymphocyte Subsets Expressing Distinct Molecules in Metastatic Melanoma Patients' Differential Loss of T Cell Signaling (1999) (0)
- Differences between in Vivoand in Vitro Activation of Cancer Patient Lymphocytes by Recombinant Inter leukin 2 : Possible Role for Lymphokine-activated Killer Cell Infusion in the in F / vo-induccd Activation 1 (2006) (0)
- Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study (2013) (0)
- Involvement of somatically acquired ecotropic viruses in the immunogenicity of nude-transplanted NIH/3T3 transformed cell lines. (1992) (0)
- Ly-5.185 molecule is associated with thymic maturation of lymphocytes but not with their cytotoxic activity. (1987) (0)
- Chain Cytokines γ Common Nodes of Melanoma Patients : Role of Tumor-Invaded and Tumor-Free Lymph T Cells from + Differentiation of CD 8 Parmiani and (2003) (0)
- Treatment of in transit metastases from cutaneous melanoma by isolation perfusion (IP) with interleukin-2 (IL-2) and lymphokine activated killer cells (LAK): 356 (1993) (0)
- Binding, presentation and immunogenicity of peptides derived from melanoma antigens MART1 and GPZOO by HLA-A2 subtypes (1996) (0)
- Surgery, Radiotherapy, Chemotherapy, Hormonal Therapy (1989) (0)
- Validation of Stereotyped Immunoglobulin Heavy Chain CDR3 Sequences As Candidate Antigens for Immunotherapy of CLL (2012) (0)
- Alloimmunization-induced syngeneic antitumor immunity in balb/c mice. Abstr. (1982) (0)
- 997 Active immunization of melanoma patients with IL-2-transfected allogeneic melanoma cells. A phase I-II study (1995) (0)
- Active immunization of melanoma patients with IL-2-OR IL-4-transduced allogeneic melanoma cells (1997) (0)
- Polygenic control of the in vivo immunity to balb/c sarcomas and lymphomas. Abstr. (1980) (0)
- Therapeutic effect of chemoimmunotherapy on lymphoma bearing mice (1987) (0)
- Abstracts reprinted from journal of clinical oncology (2007) (0)
- Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16–18 October 2008 (2009) (0)
- LAG-3 (CD223) molecule is preferentially expressed in human CD4+CD25+ T cells displaying suppressor activity (2007) (0)
- Coincedent effect in the graft-versus-host reaction of BALB/c lymphoid cells derived from mice immune either to allogeneic normal tissue or to syngeneic chemically induced fibrosarcomata. (1977) (0)
- Advances in Brief Heterogeneity in Human Melanoma Cell Adhesion to Cytokine Activated Endothelial Cells Correlates with VLA-4 Expression 1 (2006) (0)
- Biological and biochemical characterization of alien h-2 antigens of a chemically induced sarcoma. Abstr. (1979) (0)
- O11 Final analysis of a phase I/II study with CV9103: An intradermally administered prostate cancer vaccine based on self-adjuvanted mRNA (RNActive®) (2012) (0)
- Vaccination with T Cell-Defined Antigens: Biological Basis and Clinical Applications (2001) (0)
- Ly-5 molecular forms in congenitally immunodeficient mice. (1984) (0)
- Activity of np-40 solubilized and enriched tata from an mca-induced balb/c sarcoma containing alien h-2k antigens. Abstr. (1979) (0)
- Reactivity of human lymphocyte clones to autologous metastatic melanoma cells. (1988) (0)
- Multiple composition of foreign alloantigens on a murine fibrosarcoma. Abstr. (1976) (0)
- Tumor vaccines (WS-070) Chairpersons: Yutaka Kawakami, Olivera Finn (2010) (0)
- Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19–22, 2011: New perspectives in the immunotherapy of cancer (2012) (0)
- Isolation of lymphocyte clones reacting against autologous human melanoma (1987) (0)
- 5-Fluorouracil (5-FU) + Cis-diamminedichloroplatinum (DDP) Treatment of Human Colorectal Tumor Xenografts (1988) (0)
- Recognition of lineage-specific antigens on melanoma and melanocytes by HLA-A2-restricted cytolytic T cell clones: 75 (1993) (0)
- Special Topics in Carcinogenesis (1975) (0)
- A TaqI RFLP at the gas-2 locus. (1989) (0)
- Potential therapeutic use of autologous human lymphocytes in metastatic melanoma: in vivo interleukin 2-activated peripheral blood lymphocytes and in vitro activated peripheral blood and tumor-infiltrating lymphocytes. (1988) (0)
- IFN-Alpha as an adjuvant in cancer immunotherapy (2006) (0)
- Role of the a$ßiIntegrin Receptor in the Proliferative Response of Quiescent Human Melanoma Cells to Fibronectin1 (2006) (0)
- Natural Cytotoxicity Receptors and MHC Initiating Cells : A Role for − Colon Cancer Human NK Cells Selective Targeting of Dieli (2013) (0)
- Cell Activation Deliver Costimulation Signal for Dendritic Molecules Expressed by Activated T Cells Human Lymphocyte Activation Gene-3 Parmiani and (2008) (0)
- Immunotherapy of cancer with interleukin-2 and lymphocytes (LAK or TIL). (1992) (0)
- Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients (2018) (0)
- In vitro lymphocyte response to autologous melanoma: clues in designing new adoptive immunotherapy protocols. (1989) (0)
- Role of the carbohydrate prosthetic groups in the biosynthesis of membrane antigens and in the H-2-restricted lysis of MBL-2 lymphoma cells. (1983) (0)
- Non-H-2 foreign alloantigens on chemically induced sarcoma cells as detected by graft-versus-host reaction [proceedings]. (1976) (0)
- present in acute promyelocytic leukemia cells representing the fusion region of the hybrid protein pml/RAR alpha Human CD4 lymphocytes specifically recognize a peptide (2011) (0)
- Retrovirus mediated expression of interleukins for the gene therapy of cancer (1997) (0)
- Active immunization of metastatic melanoma patients with IL-2 gene-transferred, allogeneic melanoma cells (1996) (0)
- Contents, Vol. 44, 1976 (1976) (0)
- 7019 Vaccination with Survivin and PSMA-derived peptides: results of a pilot study in prostate cancer patients failing radiotherapy or surgery (2009) (0)
- Erratum: Immune mechanisms in neoplasia (2005) (0)
- Cytokine gene-transduced tumor cells in cancer therapy: Tumor inhibition by non-specific and specific immune mechanisms (1993) (0)
- Vaccination with gene-modified tumor cells (1999) (0)
- “Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 (2014) (0)
- V a c c ination o f M etastatic M elanoma P atients W ith Autologous T umor-Derived H eat S hock P rotein g p96- Peptide C omplexes: C linical a nd I mmunologic F indings (2002) (0)
- Studies of cell-mediated immunity to alien h-2k-like antigens of a balb/c(h-2d) fibrosarcoma. Abstr. (1979) (0)
- A microsatellite in the coding sequence of HLA-A/B is a mutation hotspot in colon cancer with microsatellite instability. (2021) (0)
- T-cell receptor usage in T lymphocyte clones specifically recognizing human melanoma: 91 (1993) (0)
- Dendritic cells from peripheral blood cd34+ progenitors in cancer patients treated with high dose sequential theraphy (1996) (0)
- Interleukin-2 biology and immunology (1993) (0)
- Vaccination in Human Solid Tumors: Recent Progress in the Clinical Arena (2015) (0)
- Immunization of stage IV melanoma patients with MART-1 and GP100 peptides together with IFN-alpha as adjuvant results in an increased number of monocytes/dendritic cell precursors (2004) (0)
- Tumor antigens as modified normal cell surface antigens. (1983) (0)
- Immunological approach to gene therapy of melanoma: 084 (1997) (0)
- Cancer Epidemiology, Environmental Factors. (1975) (0)
- Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012 (2013) (0)
- 23 Development of heat shock cancer vaccine strategies (2004) (0)
- Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1–3 October 2009 (2010) (0)
- HLA Class II Antigens on Melanoma Cells (1990) (0)
- “Cancer Bio-Immunotherapy in Siena”: Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9–11, 2014 (2015) (0)
- T Cell Receptor (TCR) Structure of Autologous Melanoma-reactive Cytotoxic T Lymphocyte (CTL) Clones: Tumor-lnfiltrating Lymphocytes Overexpress In Vivo the TCR f3 Chain Sequence Used by an HLA-A2-restricted and Melanocyte-lineage-specific (2003) (0)
- myb That Express c-Oligodeoxynucleotides in Colon Adenocarcinoma Cell Lines Antisense myb Inhibition of Proliferation by c-Updated Version (2006) (0)
- Eradication of a disseminated BALB/c mice lymphoma by adoptive transfer of syngeneic anti-DBA/2 T lymphocytes does not require the partecipation of radiation-sensitive host cells (1985) (0)
- Screening Tests in Chemical Carcinogenesis (1976) (0)
- INV 28 Vaccination-induced myeloid suppressor cells in melanoma: phenotypic and functional characterization (2007) (0)
- Vaccination with T cell-defined antigens: biological basis and clinical applications. (2001) (0)
- Vaccination with Survivin and PSMA-derived Peptides: A Pilot Study in Prostate Cancer Patients Failing Radiotherapy or Surgery (2009) (0)
- Latency, antigenicity and ras gene activation of methyl-cholanthrene- induced murine fibrosarcomas (1987) (0)
- Recombinant interferon-gamma differently affects DQA and DRA gene expression in two human melanoma clones: transcriptional and posttranscriptional regulation. (1991) (0)
- Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 (2015) (0)
- Update on vaccines for melanoma patients (2008) (0)
- Immunological therapy of human tumors by gene-modified cellular vaccines. (2000) (0)
- Immunomodulation in Cancer Patients Treated with Interleukin-2. Induction of Non-Specific and Specific Immune Responses (1993) (0)
- Immunological and clinical effects of a multiple peptide vaccine and low-dose cyclophosphamide in prostate carcinoma patients (2016) (0)
- 1275 Preliminary clinical results of active immunization with interleukin-4 gene transfected allogeneic melanoma cells in metastatic melanoma patients (1995) (0)
- Altered peptide ligands of tumor T-cell epitopes: implications for more effective vaccine therapy in human neoplasia (2003) (0)
- In vitro detection of cell-mediated immunity to individual tumor-specific antigens of methylcholanthrene induced balb/c fibrosarcomas. Abstr. (1983) (0)
- T cell recognition of melanoma-derived antigens: Implication for peptide based immunotherapy (1997) (0)
- 23 T cell recognition of melanoma antigens and tumour progression (1999) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Giorgio Parmiani?
Giorgio Parmiani is affiliated with the following schools: